middle.news
Immutep Advances to Phase III with Strong Survival Data and $159M Cash Buffer
6:34pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Immutep Advances to Phase III with Strong Survival Data and $159M Cash Buffer
6:34pm on Sunday 1st of June, 2025 AEST
Key Points
Initiation of Phase III TACTI-004 trial in first-line metastatic NSCLC with regulatory approval
INSIGHT-003 trial reports 32.9-month median overall survival and 81% 24-month OS rate
Promising Phase IIb TACTI-003 data in head and neck cancer with PD-L1 CPS <1 patients
Strong cash reserves of A$159.26 million ensuring funding through end of calendar 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE